AI
CNTX icon

Allostery Investments’s Context Therapeutics CNTX Stock Holding History

Allostery Investments’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-950,166
Closed -$582K – 25
2025
Q1 		$582K Hold
950,166
– – 0.84% 27
2024
Q4 		$998K Buy
+950,166
New +$1.64M 1.04% 19

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Allostery Investments's CNTX Position: Q2 2025 in Review

Allostery Investments sold out of Context Therapeutics (CNTX) in Q2 2025, closing a stake of 950,166 shares — an estimated $582K sold.

Allostery Investments first reported a position in CNTX in Q4 2024 and held it in 2 quarters. The position peaked at $998K in Q4 2024. 39 funds tracked by Wall St. Rank hold CNTX as of Q2 2025.

  • Allostery Investments reported no remaining Context Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Allostery Investments sold 950,166 Context Therapeutics shares in Q2 2025, an estimated $582K.
  • Allostery Investments first reported a position in Context Therapeutics in Q4 2024 and held it in 2 quarters.
  • Allostery Investments's Context Therapeutics position peaked at $998K in Q4 2024.
  • 39 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2025.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.